期刊文献+

c-myc基因慢病毒载体的构建及其意义 被引量:7

Construction and significance of lentiviral vector with
原文传递
导出
摘要 目的构建携带c—myc基因野生型及T58A突变型的慢病毒载体。方法应用聚合酶链反应(PCR)方法扩增c—myc野生型及T58A突变型基因,利用Gateway技术构建携带绿色荧光蛋白(GFP)基因的慢病毒载体,经PCR及基因测序鉴定后,转染293FT包装细胞,产生相应慢病毒,测定其滴度。结果PCR和测序证实,构建分别携带c—myc野生型及T58A突变型基因的慢病毒载体,并包装慢病毒,病毒滴度测定结果分别为6.10×10^7、5.65×10^7TU/ml。结论成功构建含有c—myc野生型及T58A突变型基因的慢病毒载体并包装出具高效感染力的慢病毒颗粒。 Objective To construct a lentiviral vector with e-myc gene, including wild type and mutation type. Methods The lentiviral vector with green fluorescent protein (GFP) was constructed by polymerase chain reaction (PCR) and gateway technology and identified by PCR and gene sequencing, then transfeete dinto the package cells 293FT by lipofeetin to produce mature lentivirus. The virus titer was measured. Results According to PCR and gene sequencing, the mye-lentiviral vectors were successfully constructed with the virus titer being 6. 10 x 107 ( wild type) and 5.65 x 107 ( mutation type) TU/ml, re- spectively. Conclusion The mye-lentiviral vector was successfully constructed and efficient lentivirus par- tieles were packaged.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2011年第4期543-546,I0003,共5页 Chinese Journal of Experimental Surgery
基金 基金项日:山东省自然科学基金资助项目(Y2007C134)
关键词 C-MYC基因 慢病毒 GATEWAY技术 C-mye gene Lentivims Gateway technology
分类号 Q [生物学]
  • 相关文献

参考文献12

二级参考文献37

  • 1张东伟,杨维良.甲状腺癌基因治疗的现状及展望[J].中华实验外科杂志,2005,22(2):255-256. 被引量:16
  • 2Reddi HV, McIver B, Grebe SK, et al. The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis. Endocrinology,2007,148:932-935.
  • 3Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgammal fusion oncogene in human thyroid carcinoma. Science,2000,289:1357-1360.
  • 4Lang BH, Lo CY, Chan WF, et al. Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre. Endocr Relat Cancer,2007,14:29-42.
  • 5Powell JG,Wang XY,Allard BL,et al. The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition. Oncogene, 2004,23:3634-3641.
  • 6Mclver B, Grebe SKG, Eberhardt NL. The PAXS/PPARγ fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Current Drug Targets-Immune, Endocrine & Metabolic Disorders, 2004,4:221-234.
  • 7Sahin M, Allard BL, Yates M, et al. PPARgamma staining as a surrogate for PAXS/PPARgamma fusion oncogene expression in follicular neoplasms:clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab,2005,90:463-468.
  • 8Abbas-Terki T, Blanco-Bose W, Deglon N, et al. Lentiviral mediated RNA interference. Hum Gene Ther,2002 ,13 :2197-2201.
  • 9An DS, Xie Y, Mao SH, et al. Efficient lentiviral vectors for short hairpin RNA delivery into human cells. Hum Gene Ther,2003,14:1207- 1212.
  • 10Anthony RV,Cantlon JD. RNA Interference:a new approach to the in vivo study of gene function. J Anim Sci ,2007,85 : 18-19.

共引文献44

同被引文献52

  • 1翟荣林,王国斌,夏泽峰.c-myc靶向小干扰RNA诱导乳腺癌细胞凋亡的作用[J].中华实验外科杂志,2005,22(6):698-700. 被引量:21
  • 2马锴,沈毅.survivin和c-myc在食管鳞癌组织表达及其意义[J].齐鲁医学杂志,2006,21(2):106-108. 被引量:7
  • 3Stefani G,Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol,2008,9:219-230.
  • 4Yanaihara N,Caplen N,Bowman E,et al. Unique microRNA molecu- lar profiles in lung cancer diagnosis and prognosis. Cancer Ce11,2006, 9:189-198.
  • 5Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression de- regulation in human breast cancer. Cancer Res,2005 ,65 :7065-7070.
  • 6Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of mi- croRNA expression patterns in hepatocellular carcinoma and non-tu- morous tissues. Oneogene ,2006,25:2537-2545.
  • 7Johnson SM,Grosshans H, Shingara J, et al. RAS is regulated by the let-7 MicroRNA family. Ce11,2005,120:635-647.
  • 8Kim HH,Kuwano Y,Srikantan S, et al. ttuR recruits Iet-7/RISC to repress c-Myc expression. Genes Dev,2009,23 : 1743-1748.
  • 9Boyerinas B, Park SM, Hau A, et a]. The role of let-7 in cell differenti- ation and cancer. Endocr Relat Cancer,2010,17 : FI9-F36.
  • 10Shimizu S,Takehara T, Hikita H,et al. The let-7 family of microRNAs inhibits Bel-xL expression and potentiates sorafenib-induced apoptosis in human hepatoeellular carcinoma. J Hepatol,2010 ,52 :698-704.

引证文献7

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部